Back

Comparative outcomes between empagliflozin and dapagliflozin in heart failure: real world multi-center cohort study

31 August 2024 (10:10 - 10:20)
Organised by: Logo
Congress Presentation Part of: Further Insights into SGLT2i treatment for heart failure Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Seonghyeon Bu

St Mary hospital, Uijeongbu (Korea (Republic of))

5 More presentations in this session

Presentation thumbnail
Effects of dapagliflozin according to QRS duration across the spectrum of LVEF: An analysis of DAPA-HF and DELIVER
Associate Professor A. Abdin (Homburg, DE)
Abstract Slides Video
Presentation thumbnail
Randomized trial assessing worsening renal function with dapagliflozin addition in acute decompensated heart failure: ROAD-ADHF trial
Doctor S. Kawanami (Sakai, JP)
Abstract Slides Video
Presentation thumbnail
The effects of SGLT2 inhibitors on right ventricle functions in heart failure patients: update meta-analysis of the current literature
Doctor A. Erdem (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
Effects of dapagliflozin on body composition and its relation to hemodynamics in heart failure with preserved ejection fraction: the CAMEO-DAPA randomized clinical trial
Assistant Professor J. Naser (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Effectiveness of empagliflozin in patients with heart failure and COPD: Results from EMPEROR-Preserved and EMPEROR-Reduced
Professor S. von Haehling (Goettingen, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Further Insights into SGLT2i treatment for heart failure
Video

The Event

Event poster

ESC Congress 2024

31 August 2024 10:10 CET
You may be interested in
thumbnail
Congress Presentation
Outcomes of empagliflozin versus dapagliflozin treatment in patients with heart failure based on left ventricular ejection fraction: a multicentre cohort study
thumbnail
Congress Presentation
A real-world population with HFrEF treated with dapagliflozin or empagliflozin: a comparative analysis with DAPA-HF and EMPEROR REDUCED studies
thumbnail
Congress Presentation
Dapagliflozin versus empagliflozin in patients with heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources